Citations

Mayo Clinic

Showing 10 of 108537 citations.

How accurate do self‐reported seizures need to be for effective medication management in epilepsy?
Goldenholz, Daniel M. , Brinkmann, Benjamin H. , Goldenholz, Daniel M , Brinkmann, Benjamin H , Westover, M. Brandon

Epilepsia | May 22, 2024 | Volume: 65 | Issue: 7 | Pages: No page available

10.1111/epi.18019 | PMID 38776216 Get It

AbstractStudies suggest that self‐reported seizure diaries suffer from 50% under‐reporting on average. It is unknown to what extent this impacts medication management. This study used simulation to predict the seizure outcomes of a large heterogeneous clinic population treated with a standardized algorithm based on self‐reported seizures. Using CHOCOLATES, a state‐of‐the‐art realistic seizure diary simulator, 100 000 patients were simulated over 10 years. A standard algorithm for medication management was employed at 3 month intervals for all patients. The impact on true seizure rates, expected seizure rates, and time‐to‐steady‐dose were computed for self‐reporting sensitivities 0%–100%. Time‐to‐steady‐dose and medication use mostly did not depend on sensitivity. True seizure rate decreased minimally with increasing self‐reporting in a non‐linear fashion, with the largest decreases at low sensitivity rates (0%–10%). This study suggests that an extremely wide range of sensitivity will have similar seizure outcomes when patients are clinically treated using an algorithm similar to the one presented. Conversely, patients with sensitivity ≤10% would be expected to benefit (via lower seizure rates) from objective devices that provide even small improvements in seizure sensitivity.
Out-of-Pocket Costs Among Commercially Insured Individuals With Type 2 Diabetes and Obesity
Wall‐Wieler, Elizabeth , Liu, Yuki , Zheng, Feibi , Coviello, Andrea, Edwards, Michael A. , Coviello, Andrea D.

Annals of Surgery | May 22, 2024 | Volume: 281 | Issue: 2 | Pages: 196-200

10.1097/sla.0000000000006353 | PMID 38775477 Get It

Objective: To determine out-of-pocket (OOP) costs 2 years after sleeve gastrectomy (SG) or initiating Ozempic for patients with type 2 diabetes (T2D) and obesity. Background: Individuals with obesity and T2D have a variety of treatment options. The risks and benefits of these treatment options are becoming more well-documented; however, the real-world patient costs of these options are not known. Methods: Adults with body mass index of 35 kg/m2 or higher and T2D who had an SG or used Ozempic were identified in the employer-based retrospective claims database Merative (previously Truven IBM Marketscan) from 2017 to 2021. SG cohort was defined as having an SG (without filling a prescription for Ozempic), and the Ozempic cohort was defined as continuously filling a prescription for Ozempic for at least 2 years (and not having any bariatric surgery). Individuals in each cohort were 1:1 propensity matched on demographics, obesity-related comorbidities, and baseline OOP costs. in the year before treatment. OOP costs were compared in the 2 years after treatment using paired t tests. Results: A total of 302 SGs were matched to 302 Ozempic patients (mean age: 50, mean baseline body mass index: 40, 41% males). OOP health care costs were similar for the SG ($2267) and Ozempic ($2131) cohorts 1 year after the index date (difference = $136, P = 0.19). OOP health care costs were significantly lower in the SG cohort ($1155 vs $2,084, P < 0.01) 2 years after the index date. Conclusions: Within 2 years of starting treatment, OOP health care costs were significantly lower among individuals who had a SG versus those treated with Ozempic.
USP44 Overexpression Drives a MYC-Like Gene Expression Program in Neuroblastoma through Epigenetic Reprogramming
Ekstrom, Thomas L. , Hussain, Sajjad , Bedekovics, Tibor , Ali, Asma , Paolini, Lucia , Mahmood, Hina , Rosok, Raya M. , Köster, Jan , Johnsen, Steven A. , Galardy, Paul J. , Johnsen, Steven A , Bedekovics, Tibor

Molecular Cancer Research | May 22, 2024 | Volume: 22 | Issue: 9 | Pages: 812-825

10.1158/1541-7786.mcr-23-0454 | PMID 38775808 Get It

Abstract Neuroblastoma is an embryonic cancer that contributes disproportionately to death in young children. Sequencing data have uncovered few recurrently mutated genes in this cancer, although epigenetic pathways have been implicated in disease pathogenesis. We used an expression-based computational screen that examined the impact of deubiquitinating enzymes on patient survival to identify potential new targets. We identified the histone H2B deubiquitinating enzyme USP44 as the enzyme with the greatest impact on survival in patients with neuroblastoma. High levels of USP44 significantly correlate with metastatic disease, unfavorable histology, advanced patient age, and MYCN amplification. The subset of patients with tumors expressing high levels of USP44 had significantly worse survival, including those with tumors lacking MYCN amplification. We showed experimentally that USP44 regulates neuroblastoma cell proliferation, migration, invasion, and neuronal development. Depletion of the histone H2B ubiquitin ligase subunit RNF20 resulted in similar findings, strongly implicating this histone mark as the target of USP44 activity in this disease. Integration of transcriptome and epigenome in analyses demonstrates a distinct set of genes that are regulated by USP44, including those in Hallmark MYC target genes in both murine embryonic fibroblasts and the SH-SY5Y neuroblastoma cell line. We conclude that USP44 is a novel epigenetic regulator that promotes aggressive features and may be a novel target in neuroblastoma. Implications: This study identifies a new genetic marker of aggressive neuroblastoma and identifies the mechanisms by which its overactivity contributes to the pathophysiology of this disease.
Management of cardiac sarcoidosis
Sharma, Rakesh , Metra, Marco , Heidecker, Bettina , Baksi, John, Wicks, Eleanor , Tschöpe, Carsten , Petersen, Steffen E. , Lüscher, Thomas F. , Filippatos, Gerasimos , Metra, Marco , Klingel, Karin , Imazio, Massimo , Petersen, Steffen E , Heidecker, Bettina , Tschöpe, Carsten , Sharma, Rakesh , Kouranos, Vasileios , Cooper, Leslie T. , Ristić, Arsen , Merino, José Luís , Imazio, Massimo , Chillou, Christian de , Kuchynka, Petr , McDonagh, Theresa A.

European Heart Journal | May 22, 2024 | Volume: 45 | Issue: 30 | Pages: 2697-2726

10.1093/eurheartj/ehae356 | PMID 38923509 Get It

Abstract Cardiac sarcoidosis (CS) is a form of inflammatory cardiomyopathy associated with significant clinical complications such as high-degree atrioventricular block, ventricular tachycardia, and heart failure as well as sudden cardiac death. It is therefore important to provide an expert consensus statement summarizing the role of different available diagnostic tools and emphasizing the importance of a multidisciplinary approach. By integrating clinical information and the results of diagnostic tests, an accurate, validated, and timely diagnosis can be made, while alternative diagnoses can be reasonably excluded. This clinical expert consensus statement reviews the evidence on the management of different CS manifestations and provides advice to practicing clinicians in the field on the role of immunosuppression and the treatment of cardiac complications based on limited published data and the experience of international CS experts. The monitoring and risk stratification of patients with CS is also covered, while controversies and future research needs are explored.
CUFFLESS BLOOD PRESSURE IN CLINICAL PRACTICE: CHALLENGES, OPPORTUNITIES AND CURRENT LIMITS
Henry, Benoît , Merz, Maxime, Hoang, Harry , Wosik, Jedrek , Henry, Benoit, Ghaith, Abdul Karim , Schoettker, Patrick

Journal of Hypertension | May 22, 2024 | Volume: 42 | Issue: Suppl 1 | Pages: e82

10.1097/01.hjh.0001020076.66245.93 Get It

Objective: Cuffless blood pressure measurement technologies have attracted significant attention for their potential to transform cardiovascular monitoring. This updated narrative review thoroughly examines the challenges, opportunities, and limitations associated with the implementation of cuffless blood pressure monitoring systems. By summarizing the current state of the art and identifying future directions, this article aims to participate in the debate around cuffless BP measurement while contributing substantial scientific value to this rapidly evolving field. Design and method: The search procedure involved using Google Scholar and PubMed databases. During the initial search, a substantial number of articles unrelated to this literature survey were retrieved. Authors then selected the articles that were relevant for this review on cuffless noninvasive BP measurement. Results: Diverse technologies, including photoplethysmography, tonometry, and ECG waveform analysis, enable cuffless blood pressure measurement and are integrated into devices like smartphones and smartwatches. Signal processing emerges as a critical aspect, dictating the accuracy and reliability of readings. Despite its potential, the integration of cuffless technologies into clinical practice faces obstacles, including the need to address concerns related to accuracy, calibration, and standardization across diverse devices and patient populations. The development of robust algorithms to mitigate artifacts and environmental disturbances is essential for extracting clear physiological signals. Based on extensive research, this review emphasizes the necessity for standardized protocols, validation studies, and regulatory frameworks to ensure the reliability and safety of cuffless blood pressure monitoring devices and their implementation in mainstream medical practice. Interdisciplinary collaborations between engineers, clinicians, and regulatory bodies are crucial to address technical, clinical, and regulatory complexities during implementation. Conclusions: While cuffless blood pressure monitoring holds immense potential to transform cardiovascular care. The resolution of existing challenges and the establishment of rigorous standards are imperative for its seamless incorporation into routine clinical practice. The emergence of these new technologies shifts the paradigm of cardiovascular health management, presenting a new possibility for non-invasive continuous and dynamic monitoring. The concept of cuffless blood pressure measurement is viable and more finely tuned devices are expected to enter the market, which could redefine our understanding of blood pressure and hypertension.
A NOVEL ELECTRO-HYDRAULIC ACOUSTIC THERAPY REDUCES BLOOD PRESSURE IN HYPERTENSIVE PATIENTS WITH CHRONIC KIDNEY DISEASE: 12-MONTH FOLLOW-UP
Wolak, Talya , Glikson, Michael , Sukholutsky, Ivetta, Silberman, Shuli, Lerman, Lilach O. , Lerman, Amir , Glikson, Michael

Journal of Hypertension | May 22, 2024 | Volume: 42 | Issue: Suppl 1 | Pages: e17-e18

10.1097/01.hjh.0001019472.74082.65 Get It

Objective: Arterial hypertension (HTN) coexisting with chronic kidney disease (CKD) presents a significant global healthcare challenge, with limited effective clinical interventions. Electro-Hydraulic Acoustic Therapy (eHAT), a lower-energy modality vs. lithotripsy, emerges as a promising technique for relieving ischemia and promoting tissue regeneration. We hypothesized that eHAT would reduce blood pressure (BP) and preserve renal function in patients with hypertension and CKD. Design and method: Twenty medically treated patients with HTN and Stage IIIa/b CKD enrolled in this prospective, single-arm study were treated over 3-weeks with six eHAT sessions (2400 shockwaves/kidney; 0.09 mJ/mm2 at 2.66Hz; NephrospecTM, Curespec, Yehud, Israel). Follow-up (FU) visits at 1, 3, 6, and 12 months involved measurements of attended and unattended office BP, ambulatory BP and estimated glomerular filtration rate (eGFR). Results: The treatment was well tolerated. All BP measurements strongly tended to decline over 12 months and showed a similar pattern.(Table 1, Figs. 1-3), whereas eGFR was well preserved (Table 1, Fig. 4). Conclusions: Conclusion. eHAT is a tolerable and safe procedure and, moreover, a 3-week regimen tends to reduce BP and preserve eGFR in patients with HTN and CKD. Therefore, eHAT may constitute a novel, safe, and non-invasive alternative therapeutic approach in the management of HTN in the context of CKD.
Clinical and Surgical Applications of Large Language Models: A Systematic Review
Pressman, Sophia M. , Borna, Sahar , Gomez-Cabello, Cesar A. , Haider, Syed Ali , Haider, Clifton R. , Forte, Antonio J. , Forte, Antonio Jorge , Borna, Sahar , Pressman, Sophia , Gomez-Cabello, Cesar A , Haider, Syed A

Journal of Clinical Medicine | May 22, 2024 | Volume: 13 | Issue: 11 | Pages: 3041

10.3390/jcm13113041 | PMID 38892752 Get It

Background: Large language models (LLMs) represent a recent advancement in artificial intelligence with medical applications across various healthcare domains. The objective of this review is to highlight how LLMs can be utilized by clinicians and surgeons in their everyday practice. Methods: A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Six databases were searched to identify relevant articles. Eligibility criteria emphasized articles focused primarily on clinical and surgical applications of LLMs. Results: The literature search yielded 333 results, with 34 meeting eligibility criteria. All articles were from 2023. There were 14 original research articles, four letters, one interview, and 15 review articles. These articles covered a wide variety of medical specialties, including various surgical subspecialties. Conclusions: LLMs have the potential to enhance healthcare delivery. In clinical settings, LLMs can assist in diagnosis, treatment guidance, patient triage, physician knowledge augmentation, and administrative tasks. In surgical settings, LLMs can assist surgeons with documentation, surgical planning, and intraoperative guidance. However, addressing their limitations and concerns, particularly those related to accuracy and biases, is crucial. LLMs should be viewed as tools to complement, not replace, the expertise of healthcare professionals.
Indurated Subcutaneous Thigh Nodules: Challenge
Onalaja-Underwood, Amanda A. , Pincelli, Thaís , Sokumbi, Olayemi

The American Journal of Dermatopathology | May 22, 2024 | Volume: 46 | Issue: 6 | Pages: e42-e43

10.1097/dad.0000000000002614 | PMID 40522951 Get It

Indurated Subcutaneous Thigh Nodules: Answer
Onalaja-Underwood, Amanda A. , Pincelli, Thaís , Sokumbi, Olayemi

The American Journal of Dermatopathology | May 22, 2024 | Volume: 46 | Issue: 6 | Pages: 393-394

10.1097/dad.0000000000002615 | PMID 39121201 Get It

Cyclic vomiting syndrome: Future clinical and research priorities
Li, B U.K. , Levinthal, David J. , Venkatesan, Thangam , Hasler, William L. , Li, B U K , Levinthal, David J , Venkatesan, Thangam

Neurogastroenterology & Motility | May 22, 2024 | Volume: 37 | Issue: 3 | Pages: No page available

10.1111/nmo.14825 | PMID 38775195 Get It

AbstractBackgroundAn increasing number of studies have explored the clinical features, epidemiology, pathophysiology, and management of cyclic vomiting syndrome (CVS). CVS is common in adults and children and negatively impacts patients, families, and the healthcare system. A related condition, cannabinoid hyperemesis syndrome (CHS), has been a focus of interest in the lay press and published literature.PurposeClinical presentations of CVS have been defined by small series and expert opinion, but recent prospective studies are refining our understanding of the spectrum of emetic episodes and the breadth of comorbid conditions. Large cross‐sectional population analyses are clarifying CVS prevalence and factors related to age, ethnicity, and geographic region. CVS pathophysiology is multifactorial with contributions from migraines, dysautonomia, endogenous cannabinoids, mitochondrial dysfunction, genetic abnormalities, and rapid gastric emptying. CVS treatment relies on antiemetics and antimigraine therapies to abort acute episodes coupled with prophylactic regimens employing neuromodulators and antiepileptics. CHS represents a challenge partly because of difficulties in achieving sustained cannabis abstinence. Benefits of other therapies in CHS remain poorly defined. Several areas warrant further scrutiny including better identification of CVS triggers and characterization of different CVS subsets including those with frequent severe episodes, refined description of epidemiology to allow targeting of populations predisposed to CVS development, rigorous definition of pathogenic factors to provide a foundation for exploratory studies of novel therapies, and conduct of controlled trials by multicenter collaborations to confirm benefits of existing and new therapies in development. Progress in these areas will be facilitated by generous governmental and industry support.